Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study

被引：0
|
作者：
Rohit Aggarwal
Joachim Schessl
Christina Charles-Schoeman
Zsuzsanna Bata-Csörgő
Mazen M. Dimachkie
Zoltan Griger
Sergey Moiseev
Chester V. Oddis
Elena Schiopu
Jiri Vencovský
Irene Beckmann
Elisabeth Clodi
Todd Levine
机构：
[1] University of Pittsburgh School of Medicine,Division of Rheumatology and Clinical Immunology
[2] Friedrich-Baur-Institute,Department of Neurology
[3] Ludwig-Maximilians University of Munich,Department of Dermatology and Allergology
[4] University of California,Department of Neurology
[5] University of Szeged,Division of Clinical Immunology, Faculty of Medicine
[6] University of Kansas Medical Center,Tareev Clinic of Internal Diseases
[7] University of Debrecen,Division of Rheumatology
[8] Sechenov First Moscow State Medical University,Institute of Rheumatology and Department of Rheumatology, 1st Medical Faculty
[9] Medical College of Georgia at Augusta University,undefined
[10] Charles University,undefined
[11] Octapharma Pharmazeutika Produktionsges. m.b.H.,undefined
[12] Phoenix Neurological Associates,undefined
[13] Ltd,undefined
来源：
Arthritis Research & Therapy | / 26卷
关键词：
Dermatomyositis; Intravenous immunoglobulin; Myositis; Safety; Tolerability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study
    Aggarwal, Rohit
    Schessl, Joachim
    Charles-Schoeman, Christina
    Bata-Csorgo, Zsuzsanna
    Dimachkie, Mazen M.
    Griger, Zoltan
    Moiseev, Sergey
    Oddis, Chester V.
    Schiopu, Elena
    Vencovsky, Jiri
    Beckmann, Irene
    Clodi, Elisabeth
    Levine, Todd
    [J]. ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [2] Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)
    Aggarwal, Rohit
    Charles-Schoeman, Christina
    Schessl, Joachim
    Bata-Csorgo, Zsuzsanna
    Dimachkie, Mazen
    Griger, Zoltan
    Moiseev, Sergey
    Oddis, Chester
    Schiopu, Elena
    Vencovsky, Jiri
    Irene, Beckmann
    Elisabeth, Clodi
    Levine, Todd
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [3] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG 10% IN PATIENTS WITH DERMATOMYOSITIS. THE PRODERM STUDY: RESULTS ON EFFICACY AND SAFETY
    Aggarwal, R.
    Charles-Schoeman, C.
    Schessl, J.
    Bata-Csorgo, Z.
    Dimachkie, M.
    Griger, Z.
    Moiseev, S.
    Oddis, C. V.
    Schiopu, E.
    Vencovsky, J.
    Beckmann, I.
    Levine, T.
    Clodi, E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 4 - 5
  • [4] EVALUATING EFFICACY AND SAFETY OF A 10% INTRAVENOUS IMMUNOGLOBULIN SOLUTION IN PATIENTS WITH DERMATOMYOSITIS (PRODERM STUDY) - DESIGN OF A PHASE III STUDY
    Aggarwal, R.
    Charles-Schoeman, C.
    Schessl, J.
    Levine, T.
    [J]. MUSCLE & NERVE, 2017, 56 : S10 - S10
  • [5] Levetiracetam intravenous infusion: A randomised placebo-controlled safety study.
    Ramael, S
    Troenaru, M
    Toublanc, N
    Daoust, A
    Otoul, C
    Lu, Z
    Stockis, A
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P81 - P81
  • [6] THE PRODERM STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG (OCTAGAM 10%) IN PATIENTS WITH ACTIVE DERMATOMYOSITIS
    Aggarwal, R.
    Charles-Schoeman, C.
    Schessl, J.
    Bata-Csorgo, Z.
    Dimachkie, M. M.
    Griger, Z.
    Moiseev, S.
    Oddis, C. V.
    Schiopu, E.
    Vencovsky, J.
    Beck-Mann, I.
    Clodi, E.
    Levine, T.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 428 - 429
  • [7] Safety and tolerability of MEDI-551 in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
    Agius, M.
    Klodowska-Duda, G.
    Maciejowski, M.
    Potemkowski, A.
    Sweeny, S.
    Li, J.
    Yao, W.
    Patra, K.
    Ratchford, J. N.
    Katz, E.
    Flor, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 235 - 236
  • [8] Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study")
    Aggarwal, Rohit
    Charles-Schoeman, Christina
    Schessl, Joachim
    Dimachkie, Mazen M.
    Beckmann, Irene
    Levine, Todd
    [J]. MEDICINE, 2021, 100 (01) : E23677
  • [9] Safety and Tolerability of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
    Aggarwal, Rohit
    Charles-Schoeman, Christina
    Schessl, Joachim
    Bata-Csorgo, Zsuzsanna
    Dimachkie, Mazen
    Griger, Zoltan
    Moiseev, Sergey
    Oddis, Chester
    Schiopu, Elena
    Vencovsky, Jiri
    Beckmann, Irene
    Clodi, Elisabeth
    Levine, Todd
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1409 - 1412
  • [10] Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
    Brunner, Hermine, I
    Abud-Mendoza, Carlos
    Viola, Diego O.
    Calvo Penades, Inmaculada
    Levy, Deborah
    Anton, Jordi
    Calderon, Julia E.
    Chasnyk, Vyacheslav G.
    Ferrandiz, Manuel A.
    Keltsev, Vladimir
    Paz Gastanaga, Maria E.
    Shishov, Michael
    Boteanu, Alina Lucica
    Henrickson, Michael
    Bass, Damon
    Clark, Kenneth
    Hammer, Anne
    Ji, Beulah N.
    Nino, Antonio
    Roth, David A.
    Struemper, Herbert
    Wang, Mei-Lun
    Martini, Alberto
    Lovell, Daniel
    Ruperto, Nicolino
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (10) : 1340 - 1348
12345